Drug Profile
Asciminib - Novartis
Alternative Names: ABL 001; ABL-001 - Novartis; Asciminib hydrochloride - Novartis; Scemblix; Scemblix asciminib; STAMP inhibitor - NovartisLatest Information Update: 10 Jan 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; Novartis Pharmaceuticals Corporation
- Class Amides; Antineoplastics; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Phenyl ethers; Pyrazoles; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 08 Jan 2024 Efficacy and adverse event data from phase III ASC4First trial in Chronic myeloid leukaemia released by Novartis
- 09 Dec 2023 Adverse events and efficacy data from a phase IIIb AIM4CML trial in Chronic myeloid leukemia presented at the65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 09 Dec 2023 Efficacy and adverse events data from a phase II ASC4MORE trial in Chronic myeloid leukaemia presented at 65th American Society of Hematology Annual Meeting and Exposition 2023 (ASH-Hem-2023)